Screening of prognostic risk microRNAs for acute myeloid leukemia

Hematology
Hai-Yan GaoXiao-Yun Li

Abstract

Objectives This study aimed to investigate the risk miRNAs (microRNAs) for AML (acute myeloid leukemia) prognosis and related regulatory mechanisms. Methods MiRNA and gene expression data, as well as clinical data of 176 patients were first downloaded from TCGA. Then miRNAs and genes significantly affecting the survival time based on KM survival curve were identified using Log Rank test. Next, COX proportional-hazard regression analysis was performed to screen the risk miRNAs (P-value < 0.05). Common genes from survival analysis and predicted by miRWalk were used to construct the miRNA regulatory network with the risk miRNAs. Finally, a protein-protein interaction (PPI) network was constructed, as well as functional annotation and pathway enrichment analysis. Results The survival analysis revealed 33 miRNAs and 1,377 genes significantly affecting the survival time. HR values of nine miRNAs (up-regulated hsa-mir-606, 520a, 137, 362, 599, 600, 202, 639and down-regulated 502) were either >1 or <1. The miRNA regulatory network contained 477 nodes and 944 edges. The top ten genes of the constructed PPI network were EGFR, EIF4G1, REL, TOP1, COL14A1, HDAC3, MRPL49, PSMA2, TOP2A and VCAM1 successively. According to pathway enrichment a...Continue Reading

References

Nov 4, 2000·Nature Genetics·S C TsaiE Seto
Apr 21, 2001·Blood·M ToyotaJ P Issa
Mar 21, 2002·Nature Reviews. Cancer·P MarksW K Kelly
Feb 3, 2004·Oncogene·Thomas D GilmoreDaniel T Starczynowski
Mar 24, 2004·Cancer Genetics and Cytogenetics·Leonardo PotenzaGiuseppe Torelli
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingRoss L Levine
Oct 25, 2006·Nature Reviews. Cancer·George A Calin, Carlo M Croce
Dec 7, 2007·Proceedings of the National Academy of Sciences of the United States of America·Shuangli MiJianjun Chen
May 3, 2008·The New England Journal of Medicine·Guido MarcucciClara D Bloomfield
Sep 9, 2009·The Journal of Biological Chemistry·Taeko WadaYusuke Furukawa
Nov 12, 2009·Blood·Lars BullingerDirk van den Boom
Sep 22, 2010·Nucleic Acids Research·Amanda C GentryNeil Osheroff
May 25, 2011·Journal of Biomedical Informatics·Harsh DweepNorbert Gretz
Nov 11, 2011·Wiley Interdisciplinary Reviews. RNA·Shobha Vasudevan
Jul 25, 2012·BMC Cancer·Anne MuratiDaniel Birnbaum
Dec 4, 2012·Nucleic Acids Research·Andrea FranceschiniLars J Jensen

❮ Previous
Next ❯

Citations

Mar 17, 2020·Cancer Biomarkers : Section a of Disease Markers·Xia LinJie Jin
Nov 27, 2020·International Journal of Molecular Sciences·Guomin HuangHong Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.